ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Takeda Bags Big Vaccine Subsidy

by Jean-François Tremblay
August 29, 2011 | APPEARED IN VOLUME 89, ISSUE 35

The Japanese government has awarded Takeda Pharmaceutical $312 million to help it invest in pandemic H5N1 flu vaccine development and manufacturing. The company is in the process of implementing in Japan a flu vaccine technology, based on Vero cells, that it licensed from Baxter International. Takeda will proceed with the construction of a commercial facility at its Hikari site, with the aim of obtaining regulatory approval for its vaccines during the 2013 fiscal year. Last year, Japan provided $47 million for the company to test Baxter’s cell-culture and purification techniques at Hikari.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment